Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Myocardial preservation using HTK solution for heart transplantation

Myocardial preservation using HTK solution for heart transplantation • European Journal of -- CardlOthoracic Letters to the editor Surgery © Springer-Verlag 1994 Eur J Cardio-thorac Surg (1994) 8:337 The first 100 transplanted patients of the Bad Oeynhausen's pa- Myocardial preservation using HTK solution tients collective were included in the HTK study. for heart transplantation One patient only, prior to retransplantation, received a prophy- lactic dose with R-ATG preoperatively and the first 3 days postop- Eur J Cardio-thorac Surg (1993) 7:414-419 eratively. This means not 97% of the patients of the HTK study were treated with standard quadruple drug therapy, but only M.M. K6rner, H. Posival, R. Kfrfer 83.5%. We have completely avoided using monoclonal or polyclonal Herzzentrum Nordrhein-Westfalen, Universit/itsklinik der Ruhr- antibody prophylaxis; additionally our recipients were treated with Universit/it Bochum, Klinik ffir Thorax- und Kardiovaskular- methylprednisolone before release of the aortic cross-clamp, and chirurgie, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany not after release of the aortic cross-clamp. Moreover, the adult patients were treated with 4 x 250 mg methylprednisolone within the first 3 postoperative days. We could avoid using oral prednisolone in approximately 65% Received for publication: November 4, 1993 of our patients. Accepted for publication: January 13, 1994 Correspondence to: M. M. K6rner, M.D. Reply 83.5% instead of 97% as mentioned in the text. The administration of methylprednisolone immediately before of after release of the aortic cross-clamp should not make any difference to the patient's H. Reichenspurner outcome after transplantation. Department of Cardiac Surgery, University Hospital However, it needs to be emphasized that these minor modifica- Munich-Grosshadern, D-81366 Miinchen, Germany tions of immunosuppression certainly do not influence the outcome when looking at the protective property of a myocardial preserva- tion solution. As mentioned in the text, multivariate analysis was carried out in the study before calculating statistical significance. With regard to the letter to the Editor by M. K6rner et al. we would Finally it should be mentioned that before publication the man- like to confirm that due to a typing error the percentage of patients uscript was handed to all co-authors or to the heads of their institu- treated with standard quadruple drug immunosuppression was tions before submission to the journal. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cardio-Thoracic Surgery Oxford University Press

Myocardial preservation using HTK solution for heart transplantation

European Journal of Cardio-Thoracic Surgery , Volume 8 (6) – Jun 1, 1994
Download PDF
1 page

Loading next page...
 
/lp/oxford-university-press/myocardial-preservation-using-htk-solution-for-heart-transplantation-Q60NvyaT87

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
© Springer-Verlag 1994
ISSN
1010-7940
eISSN
1873-734X
DOI
10.1016/S1010-7940(05)80096-X
Publisher site
See Article on Publisher Site

Abstract

• European Journal of -- CardlOthoracic Letters to the editor Surgery © Springer-Verlag 1994 Eur J Cardio-thorac Surg (1994) 8:337 The first 100 transplanted patients of the Bad Oeynhausen's pa- Myocardial preservation using HTK solution tients collective were included in the HTK study. for heart transplantation One patient only, prior to retransplantation, received a prophy- lactic dose with R-ATG preoperatively and the first 3 days postop- Eur J Cardio-thorac Surg (1993) 7:414-419 eratively. This means not 97% of the patients of the HTK study were treated with standard quadruple drug therapy, but only M.M. K6rner, H. Posival, R. Kfrfer 83.5%. We have completely avoided using monoclonal or polyclonal Herzzentrum Nordrhein-Westfalen, Universit/itsklinik der Ruhr- antibody prophylaxis; additionally our recipients were treated with Universit/it Bochum, Klinik ffir Thorax- und Kardiovaskular- methylprednisolone before release of the aortic cross-clamp, and chirurgie, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany not after release of the aortic cross-clamp. Moreover, the adult patients were treated with 4 x 250 mg methylprednisolone within the first 3 postoperative days. We could avoid using oral prednisolone in approximately 65% Received for publication: November 4, 1993 of our patients. Accepted for publication: January 13, 1994 Correspondence to: M. M. K6rner, M.D. Reply 83.5% instead of 97% as mentioned in the text. The administration of methylprednisolone immediately before of after release of the aortic cross-clamp should not make any difference to the patient's H. Reichenspurner outcome after transplantation. Department of Cardiac Surgery, University Hospital However, it needs to be emphasized that these minor modifica- Munich-Grosshadern, D-81366 Miinchen, Germany tions of immunosuppression certainly do not influence the outcome when looking at the protective property of a myocardial preserva- tion solution. As mentioned in the text, multivariate analysis was carried out in the study before calculating statistical significance. With regard to the letter to the Editor by M. K6rner et al. we would Finally it should be mentioned that before publication the man- like to confirm that due to a typing error the percentage of patients uscript was handed to all co-authors or to the heads of their institu- treated with standard quadruple drug immunosuppression was tions before submission to the journal.

Journal

European Journal of Cardio-Thoracic Surgery – Oxford University Press

Published: Jun 1, 1994

There are no references for this article.